Abstract
Fragment hopping is a fragment-based approach to designing biologically active small molecules. The key of this approach is the determination of the minimal pharmacophoric elements in the three-dimensional space. Based on the derived minimal pharmacophoric elements, new fragments with different chemotypes can be generated and positioned to the active site of the target protein. Herein, we detail a protocol for performing fragment hopping. This approach can not only explore a wide chemical space to produce new ligands with novel scaffolds but also characterize and utilize the delicate differences in the active sites between isofunctional proteins to produce new ligands with high target selectivity/specificity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1:187–192
Davis BJ, Erlanson DA (2013) Learning from our mistakes: the ‘unknown knowns’ in fragment screening. Bioorg Med Chem Lett 23:2844–2852
Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–1534
Hajduk PJ, Gerfin T, Boehlen JM, Häberli M, Marek D, Fesik SW (1999) High-throughput nuclear magnetic resonance-based screening. J Med Chem 42:2315–2317
Peng JW, Lepre CA, Fejzo J, Abdul-Manan N, Moore JM (2002) Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol 338:202–230
Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108–6117
Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B (2001) WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR 21:349–359
Mattos C, Ringe D (1996) Locating and characterizing binding sites on proteins. Nat Biotechnol 14:595–599
Lesuisse D, Lange G, Deprez P, Bénard D, Schoot B, Delettre G, Marquette JP, Broto P, Jean-Baptiste V, Bichet P, Sarubbi E, Mandine E (2002) SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem 45:2379–2387
Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48:403–413
Ciulli A, Williams G, Smith AG, Blundell TL, Abell C (2006) Probing hot spots at protein–ligand binding sites: a fragment-based approach using biophysical methods. J Med Chem 49:4992–5000
Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA (2000) Site-directed ligand discovery. Proc Natl Acad Sci U S A 97:9367–9372
Seth PP, Miyaji A, Jefferson EA, Sannes-Lowery KA, Osgood SA, Propp SS, Ranken R, Massire C, Sampath R, Ecker DJ, Swayze EE, Griffey RH (2005) SAR by MS: discovery of a new class of RNA-binding small molecules for the hepatitis C virus: internal ribosome entry site IIA subdomain. J Med Chem 48:7099–7102
Nordström H, Gossas T, Hämäläinen M, Källblad P, Nyström S, Wallberg H, Danielson UH (2008) Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem 51:3449–3459
de Kloe GE, Retra K, Geitmann M, Källblad P, Nahar T, van Elk R, Smit AB, van Muijlwijk-Koezen JE, Leurs R, Irth H, Danielson UH, de Esch IJP (2010) Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. J Med Chem 53:7192–7201
Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, Tehan B, Warne T, Congreve M (2013) Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem 56:3446–3455
Hesterkamp T, Barker J, Davenport A, Whittaker M (2007) Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. Curr Top Med Chem 7:1582–1591
Barker JJ, Barker O, Boggio R, Chauhan V, Cheng RK, Corden V, Courtney SM, Edwards N, Falque VM, Fusar F, Gardiner M, Hamelin EM, Hesterkamp T, Ichihara O, Jones RS, Mather O, Mercurio C, Minucci S, Montalbetti CA, Müller A, Patel D, Phillips BG, Varasi M, Whittaker M, Winkler D, Yarnold CJ (2009) Fragment-based identification of Hsp90 inhibitors. ChemMedChem 4:963–966
Ganesan A (1998) Strategies for the dynamic integration of combinatorial synthesis and screening. Angew Chem Int Ed 37:2828–2831
Lehn J-M, Eliseev AV (2001) Dynamic combinatorial chemistry. Science 291:2331–2332
Ramström O, Lehn J–M (2002) Drug discovery by dynamic combinatorial libraries. Nat Rev Drug Discov 1:26–36
Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, DeLano WL, Choong IC, Burdett MT, Flanagan WM, Lee D, Gordon EM, O'Brien T (2003) In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol 21:308–314
Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, DeLano WL, McDowell RS, Allen DA, Erlanson DA, Gordon EM, O'Brien T (2002) Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem 45:5005–5022
Lewis WG, Green LG, Grynszpan F, Radić Z, Carlier PR, Taylor P, Finn MG, Sharpless KB (2002) Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed 41:1053–1057
Krasiński A, Radić Z, Manetsch R, Raushel J, Taylor P, Sharpless KB, Kolb HC (2005) In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors. J Am Chem Soc 127:6686–6692
Whiting M, Muldoon J, Lin YC, Silverman SM, Lindstrom W, Olson AJ, Kolb HC, Finn MG, Sharpless KB, Elder JH, Fokin VV (2006) Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed 45:1435–1439
Babaoglu K, Shoichet BK (2006) Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2:720–723
Barelier S, Pons J, Marcillat O, Lancelin J-M, Krimm I (2010) Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem 53:2577–2588
Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, Ciulli A (2012) Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chem Biol 19:1300–1312
Krueger BA, Dietrich A, Baringhaus KH, Schneider G (2009) Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation. Comb Chem High Throughput Screen 12:383–396
Sun H, Tawa G, Wallqvist A (2012) Classification of scaffold-hopping approaches. Drug Discov Today 17:310–324
Ji H, Stanton BZ, Igarashi J, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB (2008) Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. J Am Chem Soc 130:3900–3914
Ji H, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB (2009) Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. J Med Chem 52:779–797
Lin F-Y, Tseng YJ (2011) Structure-based fragment hopping for lead optimization using predocked fragment database. J Chem Inf Model 51:1703–1715
Saluste G, Albarran MI, Alvarez RM, Rabal O, Ortega MA, Blanco C, Kurz G, Salgado A, Pevarello P, Bischoff JR, Pastor J, Oyarzabal J (2012) Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. PLoS One 7:e45964
Yu B, Huang Z, Zhang M, Dillard DR, Ji H (2013) Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement. ACS Chem Biol 8:524–529
De Luca L, Ferro S, Morreale F, Christ F, Debyser Z, Chimirri A, Gitto R (2013) Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors. J Enzyme Inhib Med Chem 28:1002–1009
Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849–857
von Itzstein M, Wu W-Y, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418–423
Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49:377–389
Miranker A, Karplus M (1991) Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 11:29–34
Zoete V, Meuwly M, Karplus M (2005) Study of the insulin dimerization: binding free energy calculations and per-residue free energy decomposition. Proteins 61:79–93
Momany FA, Rone R (1992) Validation of the general purpose QUANTA® 3.2/CHARMm® force field. J Comput Chem 13:888–900
Kastenholz MA, Pastor M, Cruciani G, Haaksma EEJ, Fox T (2000) GRID/CPCA: a new computational tool to design selective ligands. J Med Chem 43:3033–3044
Ji H, Li H, Flinspach M, Poulos TL, Silverman RB (2003) Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J Med Chem 46:5700–5711
Brenke R, Kozakov D, Chuang G-Y, Beglov D, Hall D, Landon MR, Mattos C, Vajda S (2009) Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques. Bioinformatics 25:621–627
Ngan CH, Bohnuud T, Mottarella SE, Beglov D, Villar EA, Hall DR, Kozakov D, Vajda S (2012) FTMAP: extended protein mapping with user-selected probe molecules. Nucleic Acids Res 40:W271–W275
Kortemme T, Kim DE, Baker D (2004) Computational alanine scanning of protein-protein interfaces. Sci STKE 2004(219):2
Koes D, Khoury K, Huang Y, Wang W, Bista M, Popowicz GM, Wolf S, Holak TA, Dömling A, Camacho CJ (2012) Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One 7:e32839
Koes DR, Camacho CJ (2012) Small-molecule inhibitor starting points learned from protein–protein interaction inhibitor structure. Bioinformatics 28:784–791
Koes DR, Camacho CJ (2012) PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res 40:W387–W392
Meireles LMC, Dömling AS, Camacho CJ (2010) ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res 38:W407–W411
Böhm H-J (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6:61–78
Böhm H-J, Banner DW, Weber L (1999) Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors. J Comput Aided Mol Des 13:51–56
Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541–554
Sándor M, Kiss R, Keseru GM (2010) Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model 50:1165–1172
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791
Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron 36:3219–3228
Mooij WTM, Verdonk ML (2005) General and targeted statistical potentials for protein–ligand interactions. Proteins 61:272–287
Korb O, Stützle T, Exner TE (2009) Empirical scoring functions for advanced protein–ligand docking with PLANTS. J Chem Inf Model 49:84–96
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623
Norinder U, Haeberlein M (2002) Computational approaches to the prediction of the blood–brain distribution. Adv Drug Deliv Rev 54:291–313
Clark DE (2003) In silico prediction of blood–brain barrier permeation. Drug Discov Today 8:927–933
Morelli X, Bourgeas R, Roche P (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol 15:475–481
Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R (2005) MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970–6979
Wood WJL, Patterson AW, Tsuruoka H, Jain RK, Ellman JA (2005) Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J Am Chem Soc 127:15521–15527
Patterson AW, Wood WJL, Ellman JA (2007) Substrate activity screening (SAS): a general procedure for the preparation and screening of a fragment-based non-peptidic protease substrate library for inhibitor discovery. Nat Protoc 2:424–433
Greene J, Kahn S, Savoj H, Sprague P, Teig S (1994) Chemical function queries for 3D database search. J Chem Inf Comput Sci 34:1297–1308
Barnum D, Greene J, Smellie A, Sprague P (1996) Identification of common functional configurations among molecules. J Chem Inf Comput Sci 36:563–571
Krovat EM, Langer T (2003) Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem 46:716–726
Cottrell SJ, Gillet VJ, Taylor R, Wilton DJ (2004) Generation of multiple pharmacophore hypotheses using multiobjective optimisation techniques. J Comput Aided Mol Des 18:665–682
Richmond NJ, Abrams CA, Wolohan PRN, Abrahamian E, Willett P, Clark RD (2006) GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J Comput Aided Mol Des 20:567–587
Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647–671
Sastry GM, Dixon SL, Sherman W (2011) Rapid shape-based ligand alignment and virtual screening method based on atom/feature-pair similarities and volume overlap scoring. J Chem Inf Model 51:2455–2466
Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45:160–169
Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967
Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146
Cruciani G, Watson KA (1994) Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J Med Chem 37:2589–2601
Catana C (2009) Simple idea to generate fragment and pharmacophore descriptors and their implications in chemical informatics. J Chem Inf Model 49:543–548
Cecchini M, Kolb P, Majeux N, Caflisch A (2004) Automated docking of highly flexible ligands by genetic algorithms: a critical assessment. J Comput Chem 25:412–422
Huang D, Lüthi U, Kolb P, Cecchini M, Barberis A, Caflisch A (2006) In silico discovery of β-secretase inhibitors. J Am Chem Soc 128:5436–5443
Coleman RG, Carchia M, Sterling T, Irwin JJ, Shoichet BK (2013) Ligand pose and orientational sampling in molecular docking. PLoS One 8:e75992
Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, Murray CW (2011) Docking performance of fragments and druglike compounds. J Med Chem 54:5422–5431
Budin N, Majeux N, Caflisch A (2001) Fragment-based flexible ligand docking by evolutionary optimization. Biol Chem 382:1365–1372
Acknowledgement
This work was supported by the Pulmonary Fibrosis Foundation I.M. Rosenzweig Young Investigator Award (Award number: 235170) and the Department of Defense CDMRP BCRP breakthrough award (W81XWH-13-BCRP-BREAKTHROUGH).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Teuscher, K.B., Ji, H. (2015). Protocol for Fragment Hopping. In: Klon, A. (eds) Fragment-Based Methods in Drug Discovery. Methods in Molecular Biology, vol 1289. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2486-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2486-8_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2485-1
Online ISBN: 978-1-4939-2486-8
eBook Packages: Springer Protocols